Vice President, Global Commercial Strategy Lead, Inflammation & Immunology + Rare Disease

Overview  The  Vice President, Global Commercial Strategy Lead for Inflammation & Immunology (I&I) and Rare Disease is responsible for driving long-range commercial strategy, portfolio management, and commercial success across both pipeline and inline brands. This role serves as the  single, authoritative commercial voice to R&D, Business Development, and US & International Commercial Regions , establishing clear commercial leadership to improve portfolio decision-making and trade-offs, ensure optimal launch and brand marketing strategies, and maximize global patient impact and enterprise value realization for our I&I and Rare Disease portfolio.  Reporting to the Global Commercial Strategy Lead, this leader shapes decisions on I&I and Rare Disease portfolio prioritization, lifecycle value optimization, and global marketing strategy. The position partners closely with R&D, Medical Affairs, Global Access & Value, and Regional Commercial teams to deliver breakthrough therapies addressing autoimmune, inflammatory, and rare diseases. Success in this role requires a senior commercial strategist who combines scientific depth with decisive enterprise leadership. This leader must confidently engage in complex scientific and clinical discussions, synthesize insights across R&D, Access, and Commercial teams, and convert them into clear portfolio priorities and differentiated global strategies. With full accountability for value creation, the role requires strong P&L acumen and the ability to make disciplined trade‑offs that optimize lifecycle value, launch success, and long‑term portfolio performance. The I&I and Rare Disease portfolio represents significant strategic value to realizing Pfizer's vision to achieve leadership via breakthroughs in prioritized diseases and biological axes to generate highly differentiated, multi-indication mega-blockbusters. Today, the portfolio delivers more than $10B globally with 22 ongoing clinical studies underway to significantly expand our product portfolio over the next several years.

Responsibilities  1. Long-Range Strategic Planning & Portfolio Management  Develop and execute comprehensive long-range commercial and marketing strategies for I&I and Rare Disease portfolios, encompassing pipeline assets from early development to in-line assets through commercial maturity. Serve as single, authoritative commercial voice to R&D, Commercial Regions, and Business Development strengthening commercial input from early development through launch via participation in I&I Strategy Governance Team to influence clinical development plans and investment decisions. Lead development of business cases for new product launches and lifecycle management investments. 2. Launch Excellence & Commercialization Strategy  Lead integrated global launch and marketing strategies coordinating cross-functional teams across R&D, Commercial Regions, Medical, Regulatory, Market Access, and Supply. Drive new product and indication launch readiness planning including market development activities, brand positioning, competitive assessments, and HCP/patient unmet need analysis. Own commercial asset lifecycle strategy for I&I and Rare Disease including implications of new indications and competitive dynamics    3. Commercial Excellence & Brand Strategy  Raise the bar on marketing impact, quality, and brand performance by establishing consistently higher, impact-driven standards for strategic outputs and creative excellence Lead proactive market shaping in moments that matter, anticipating and addressing threats with pre-emptive strategies. Steer Commercial prioritization of evidence generation strategies across lifecycle and Regions to enable sharper cross-functional decisions and portfolio value maximization. 4. Cross-Functional Leadership & Governance  Provide global strategic direction for in-line assets while enabling regional adaptation and tactical alignment. Own global brand strategy,